Clinical Trial Update: Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an R21 malaria vaccine containing Pfs230D1 with the Matrix-M1 adjuvant for prevention of malaria transmission and clinical mal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Matrix-M1 adjuvant (Matrix-M1 saponin-based adjuvant)
• R21 malaria vaccine (Pfs230D1-based) (Pfs230D1-based malaria vaccine with Matrix-M1 adjuvant)

Snippet

Sponsor: Serum Institute of India Pvt. Ltd. | Conditions: Prevention of Malaria Transmission and Clinical Malaria | Phase 2 | Status: RECRUITING